COPT Defense Properties $CDP Shares Acquired by Rockefeller Capital Management L.P.

Posted by Brenda Bartman on Jun 25th, 2026

Rockefeller Capital Management L.P. increased its position in shares of COPT Defense Properties (NYSE:CDP – Free Report) by 15,030.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 477,073 shares of the company’s stock after buying an additional 473,920 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in COPT Defense Properties were worth $13,263,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in CDP. UBS Group AG increased its position in shares of COPT Defense Properties by 229.6% during the fourth quarter. UBS Group AG now owns 457,210 shares of the company’s stock valued at $12,710,000 after acquiring an additional 318,493 shares during the last quarter. Easterly Investment Partners LLC lifted its holdings in shares of COPT Defense Properties by 154.2% in the 4th quarter. Easterly Investment Partners LLC now owns 299,934 shares of the company’s stock worth $8,338,000 after acquiring an additional 181,935 shares during the last quarter. Picton Mahoney Asset Management boosted its position in shares of COPT Defense Properties by 83,723.7% during the 3rd quarter. Picton Mahoney Asset Management now owns 31,853 shares of the company’s stock worth $924,000 after purchasing an additional 31,815 shares during the period. Tudor Investment Corp ET AL boosted its position in shares of COPT Defense Properties by 110.4% during the 3rd quarter. Tudor Investment Corp ET AL now owns 190,999 shares of the company’s stock worth $5,550,000 after purchasing an additional 100,224 shares during the period. Finally, Cbre Investment Management Listed Real Assets LLC increased its holdings in COPT Defense Properties by 15.8% in the 3rd quarter. Cbre Investment Management Listed Real Assets LLC now owns 1,428,203 shares of the company’s stock valued at $41,504,000 after purchasing an additional 195,149 shares during the last quarter.

COPT Defense Properties Trading Up 1.2%

Shares of CDP stock opened at $34.90 on Thursday. COPT Defense Properties has a fifty-two week low of $26.91 and a fifty-two week high of $35.06. The company has a 50 day moving average price of $32.47 and a 200 day moving average price of $31.27. The stock has a market capitalization of $3.96 billion, a P/E ratio of 25.29 and a beta of 0.79. The company has a debt-to-equity ratio of 1.63, a quick ratio of 2.85 and a current ratio of 2.85.

COPT Defense Properties (NYSE:CDP – Get Free Report) last released its earnings results on Monday, April 27th. The company reported $0.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.68 by ($0.34). COPT Defense Properties had a return on equity of 10.02% and a net margin of 20.10%.The business had revenue of $200.64 million for the quarter, compared to analyst estimates of $185.10 million. During the same quarter last year, the company earned $0.65 earnings per share. COPT Defense Properties’s quarterly revenue was up 6.8% compared to the same quarter last year. COPT Defense Properties has set its FY 2026 guidance at 2.730-2.790 EPS and its Q2 2026 guidance at 0.680-0.700 EPS. Equities research analysts predict that COPT Defense Properties will post 2.78 EPS for the current fiscal year.

COPT Defense Properties Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Tuesday, June 30th will be paid a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 3.7%. The ex-dividend date is Tuesday, June 30th. COPT Defense Properties’s dividend payout ratio (DPR) is presently 92.75%.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on CDP. Truist Financial boosted their target price on COPT Defense Properties from $33.00 to $34.00 and gave the company a “hold” rating in a research report on Monday, June 8th. JPMorgan Chase & Co. raised their price target on COPT Defense Properties from $33.00 to $34.00 and gave the stock a “neutral” rating in a research report on Friday, May 15th. Weiss Ratings raised COPT Defense Properties from a “buy (b-)” rating to a “buy (b)” rating in a research note on Tuesday, April 21st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $37.00 price objective on shares of COPT Defense Properties in a report on Wednesday, April 29th. Finally, Evercore reissued an “outperform” rating and set a $38.00 target price on shares of COPT Defense Properties in a research note on Tuesday, April 28th. Five equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, COPT Defense Properties has a consensus rating of “Moderate Buy” and an average price target of $35.00.

Get Our Latest Stock Report on CDP

Insider Transactions at COPT Defense Properties

In related news, Director Robert L. Denton sold 3,922 shares of COPT Defense Properties stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $32.38, for a total value of $126,994.36. Following the completion of the transaction, the director directly owned 3,803 shares in the company, valued at approximately $123,141.14. This trade represents a 50.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 1.66% of the company’s stock.

About COPT Defense Properties

(Free Report)

COPT Defense Properties (NYSE: CDP) is a real estate investment trust organized to own, lease and manage healthcare and life science facilities serving the United States federal government, with a particular focus on Department of Defense and Veterans Affairs tenants. The company was formed in 2016 through a spin-off from Corporate Office Properties Trust, enabling it to concentrate exclusively on medical office buildings and specialized research facilities situated on or near military and federal research campuses.

The company’s portfolio comprises purpose-built, Class A medical office and outpatient specialty clinics, as well as life science laboratories.